TRPV1 and glaucoma: As these events are particularly hazardous to RGCs, both pathological and neuroprotective aspects of TRPV1 and eCB activity may offer potential benefits for treating traumatic, inflammatory and ischemic optic neuropathies in diabetic retinopathy, ischemia, optic neuritis and glaucoma.